AR051826A1 - Composiciones inmunogenicas de antigenos polipeptidicos de staphylococcus epidermidis - Google Patents

Composiciones inmunogenicas de antigenos polipeptidicos de staphylococcus epidermidis

Info

Publication number
AR051826A1
AR051826A1 ARP050104384A ARP050104384A AR051826A1 AR 051826 A1 AR051826 A1 AR 051826A1 AR P050104384 A ARP050104384 A AR P050104384A AR P050104384 A ARP050104384 A AR P050104384A AR 051826 A1 AR051826 A1 AR 051826A1
Authority
AR
Argentina
Prior art keywords
staphylococcus epidermidis
immunogenic compositions
refers
polypeptides
polypeptidic
Prior art date
Application number
ARP050104384A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR051826A1 publication Critical patent/AR051826A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/305—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F)
    • G01N2333/31—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Abstract

La presente se refiere a composiciones inmunologicas, que comprenden polipéptidos aislados de Staphylococcus epidermidis. La presente se refiere también a polinucleotidos que codifican polipéptidos de Staphylococcus epidermidis y a su uso en composiciones inmunogénicas. Además, la presente se refiere a métodos para inducir una respuesta inmune en mamíferos contra Staphylococcus epidermidis y Staphylococcus aureus usando composiciones inmunogénicas de los polipéptidos y polinucleotidos de Staphylococcus epidermidis. Se refiere también a métodos para detectar Staphylococcus epidermidis en una muestra biologica.
ARP050104384A 2004-10-21 2005-10-20 Composiciones inmunogenicas de antigenos polipeptidicos de staphylococcus epidermidis AR051826A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62078804P 2004-10-21 2004-10-21

Publications (1)

Publication Number Publication Date
AR051826A1 true AR051826A1 (es) 2007-02-14

Family

ID=37595601

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050104384A AR051826A1 (es) 2004-10-21 2005-10-20 Composiciones inmunogenicas de antigenos polipeptidicos de staphylococcus epidermidis

Country Status (13)

Country Link
US (3) US8445000B2 (es)
EP (4) EP2298341A3 (es)
JP (2) JP2008517918A (es)
KR (1) KR20070068455A (es)
CN (1) CN101175508A (es)
AR (1) AR051826A1 (es)
AU (1) AU2005333603A1 (es)
BR (1) BRPI0516974A (es)
CA (1) CA2583121A1 (es)
IL (1) IL182546A0 (es)
TW (1) TW200619228A (es)
WO (1) WO2007001423A2 (es)
ZA (1) ZA200703274B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2468803B (en) * 2005-05-19 2011-01-19 Exocyte Ltd Screening methods for bacterial killing
ES2565377T3 (es) * 2009-04-14 2016-04-04 Glaxosmithkline Biologicals Sa Composiciones para inmunización contra Staphylococcus aureus
SG10201707084SA (en) 2009-06-22 2017-10-30 Wyeth Llc Immunogenic compositions of staphylococcus aureus antigens
EP2473630B1 (en) * 2009-09-04 2017-11-08 QIAGEN GmbH Optimized probes and primers and methods of using same for the detection, screening, isolation and sequencing of vancomycin resistance genes and vancomycin resistant enterococci
BR112014000235A8 (pt) 2011-07-06 2018-03-06 Novartis Ag emulsões de óleo em água catiônicas
AU2012280901B2 (en) 2011-07-06 2016-11-10 Glaxosmithkline Biologicals S.A. Oil-in-water emulsions that contain nucleic acids
WO2014033192A1 (en) * 2012-08-31 2014-03-06 Novartis Ag Stabilised proteins for immunising against staphylococcus aureus
WO2015144653A1 (en) * 2014-03-26 2015-10-01 Glaxosmithkline Biologicals S.A. Mutant staphylococcal antigens
AR109847A1 (es) * 2016-10-21 2019-01-30 Socpra Sciences Et Genie Sec Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus
KR102627009B1 (ko) * 2021-12-17 2024-01-19 (주)메디톡스 피부 유해 세균에 대한 항세균 활성을 갖는 세균 균주, 및 이를 포함하는 약제학적 조성물

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4837151A (en) 1980-05-19 1989-06-06 The Board Of Trustees Of The Leland Stanford Junior University, Stanford University Live vaccines comprising two mutations and foreign antigen
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
DE3751873T2 (de) 1986-04-09 1997-02-13 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
ATE237351T1 (de) 1991-11-22 2003-05-15 Univax Biolog Inc Mit staphylococcus epidermidis assoziierte oberflächenantigene des typs i
JPH07507854A (ja) 1991-12-23 1995-08-31 ツォッヒェ，ミヒャエル 油除去装置を備えたエンジン
DE69329642T3 (de) 1992-03-19 2009-05-20 Henry M. Jackson Foundation For The Advancement Of Military Medicine Breitreaktive opsonische antikörper die mit gemeinsamen antigenen von staphylococcus reagieren
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
ES2249760T3 (es) * 1993-01-26 2006-04-01 The Trustees Of The University Of Pennsylvania (A Corporation Of Pennsylvania) Composiciones y procedimientos de administracion de materias geneticas.
IL112820A0 (en) 1994-03-07 1995-05-26 Merck & Co Inc Coordinate in vivo gene expression
US6995008B1 (en) 1994-03-07 2006-02-07 Merck & Co., Inc. Coordinate in vivo gene expression
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ES2169153T3 (es) * 1994-09-21 2002-07-01 Jackson H M Found Military Med Anticuerpos opsonicos ampliamente reactivos que reaccionan con antigenos estafilococicos comunes.
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
US5700928A (en) 1995-10-16 1997-12-23 Smithkline Beecham, P.L.C. Polynucleotide encoding saliva binding protein
US6168918B1 (en) 1996-01-31 2001-01-02 American Home Products Corp. Method of detecting foreign DNA integrated in eukaryotic chromosomes
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US7060458B1 (en) * 1997-08-14 2006-06-13 Wyeth Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
US6380370B1 (en) * 1997-08-14 2002-04-30 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
EP2330192A1 (en) * 1998-08-31 2011-06-08 The Provost, Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin Polypeptides and polynucleotides from coagulase-negative staphylococci
PT1117435E (pt) 1998-09-30 2008-02-21 Us Gov Univ Health Sciences Holotoxina da cólera mutante como adjuvante
US6703492B1 (en) 1999-11-09 2004-03-09 Smithkline Beecham Corporation Staphylococcus epidermidis nucleic acids and proteins
WO2001034809A2 (en) 1999-11-09 2001-05-17 Glaxo Group Limited Staphylococcus epidermidis nucleic acids and proteins
GB0014907D0 (en) * 2000-06-20 2000-08-09 Univ Sheffield Antigenic polypeptides
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
US20020169288A1 (en) * 2001-03-15 2002-11-14 Magnus Hook Collagen-binding adhesin from staphylococcus epidermidis and method of use
DE60234695D1 (de) 2001-06-07 2010-01-21 Univ Colorado Mutantenformen von cholera holotoxin als adjuvans
IL159209A0 (en) 2001-06-07 2004-06-01 Wyeth Corp Mutant forms of cholera holotoxin as an adjuvant
CA2808598A1 (en) 2001-08-02 2003-02-13 University Of Sheffield Antigenic polypeptides
BRPI0316018B8 (pt) 2002-11-12 2021-05-25 Brigham & Womens Hospital Inc vacina polissacarídica para infecções estafilocócicas
CA2519511A1 (en) 2003-03-17 2004-09-30 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
DE602004024179D1 (de) * 2003-03-31 2009-12-31 Intercell Ag Staphylococcus epidermidis antigene
EP2305294B1 (en) 2004-09-22 2015-04-01 GlaxoSmithKline Biologicals SA Immunogenic composition for use in vaccination against staphylococcei
AU2006227536B9 (en) 2005-03-25 2011-08-18 National Research Council Of Canada Method for isolation of soluble polypeptides

Also Published As

Publication number Publication date
IL182546A0 (en) 2008-12-29
EP2340848A2 (en) 2011-07-06
EP2298341A3 (en) 2011-07-13
JP2013121981A (ja) 2013-06-20
BRPI0516974A (pt) 2008-09-30
EP2340848A3 (en) 2011-09-14
KR20070068455A (ko) 2007-06-29
WO2007001423A3 (en) 2007-11-15
AU2005333603A1 (en) 2007-01-04
EP2213298A2 (en) 2010-08-04
US20150196629A1 (en) 2015-07-16
ZA200703274B (en) 2008-06-25
EP2298341A2 (en) 2011-03-23
US20070292450A1 (en) 2007-12-20
CN101175508A (zh) 2008-05-07
US8445000B2 (en) 2013-05-21
JP2008517918A (ja) 2008-05-29
EP1802335A2 (en) 2007-07-04
US20130209501A1 (en) 2013-08-15
EP2213298A3 (en) 2011-07-20
TW200619228A (en) 2006-06-16
WO2007001423A2 (en) 2007-01-04
CA2583121A1 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
AR051826A1 (es) Composiciones inmunogenicas de antigenos polipeptidicos de staphylococcus epidermidis
CO6440592A2 (es) Composiciones para inmunizacion contra staphylococcus aureus
GT200800132A (es) Anticuerpos anti-il-23 humanos, composiciones, metodos y usos
ECSP11011115A (es) Anticuerpos anti-pd-l1 y su uso para mejorar la función de células t
AR057237A1 (es) Metodos y composiciones para actuar sobre la poliubiquitina
CR20150088A (es) Anticuerpos anti-notch1 nrr
CR20160206A (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento C5
BR0309492A (pt) Uso de pelo menos um álcool ramificado alcoxilado
CR20120310A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
ECSP077888A (es) Anticuerpos anti-il-6, composiciones, metodos y usos
BRPI0621181A8 (pt) Substâncias imunogênicas que compreendem um adjuvante a base de ácido poliinosínico - ácido policitidílico
BRPI0708344A8 (pt) Vetores adenovirais quiméricos e composição imunogênica
ECSP088831A (es) Anticuerpos anti-tat226 e inmunoconjugados
DK2468300T3 (da) Vaccinesammensætning indeholdende syntetisk adjuvant
ATE426412T1 (de) Adjuvante influenza-vakzine
WO2007052059A3 (en) Changing th1/th2 balance in split influenza vaccines with adjuvants
BRPI0619795B8 (pt) composição imunogênica, composição adjuvante, e, uso de uma composição imunogênica e um adjuvante
CY1113738T1 (el) Εμβολια κατα της γριπης χαμηλης περιεκτικοτητας σε προσθετα
BRPI0814420A2 (pt) composição, e, uso de álcool alcoxilado.
EP2441468A3 (en) Immunotherapy by using cell capable of co-expressing target antigen and cd1d and pulsed with cd1d ligand
CL2011000368A1 (es) Aparato para obtener una muestra de estigmas individuales de una barba de estigmas de una planta de maiz que comprende un primer brazo que porta dos hojas separadas, un segundo brazo, una conexion entre los brazos adaptados para permitir la traslacion de las hojas y el eje romo entre si, y sistema de obtencion de un recuento cuantitativo de trozos.
CR10280A (es) Anticuerpos de la efgl7 y metodos de uso
NO20062579L (no) Preparater som omfatter melittin-avledede peptider og fremgangsmate for styrking av immunresponser mot malantigener
CL2019000019A1 (es) Anticuerpos con baja inmunogenicidad y uso de los mismos
EA200900738A1 (ru) Слитые белки, содержащие антигены отторжения опухоли ny-eso-1 и lage-1

Legal Events

Date Code Title Description
FB Suspension of granting procedure